Skip to main content
Premium Trial:

Request an Annual Quote

CareDx, Johns Hopkins Partner on Remote Monitoring of Lung Transplant Patients

NEW YORK – CareDx and Johns Hopkins University announced on Thursday a partnership to launch the Allosure Lung Allograft Remote Monitoring (ALARM) Partnership.

During the COVID-19 pandemic, Johns Hopkins has adopted CareDx's RemoTraC for high-risk populations of kidney, heart, and lung transplant patients who need close medical monitoring. RemoTraC is a remote home-based blood draw product that uses mobile phlebotomy for AlloSure and AlloMap surveillance tests, as well as for other standard monitoring tests.

RemoTraC and AlloSure, a donor-derived cell-free DNA test, provides a potential alternative for  lung transplant patients to procedures such as bronchoscopic biopsies that need to be performed in a hospital setting and may expose patients to health risks.

During the pandemic, Johns Hopkins and CareDx are partnering to launch the ALARM Partnership to measure the impact of AlloSure and RemoTraC on lung transplant patients.

"CareDx has offered AlloSure to the lung transplant population as compassionate use, and we are now seeing the broader need with RemoTraC during these unique times," CareDx Senior VP of Medical Affairs Sham Dholakia said in a statement.